Underarm Sweating Treatment Melbourne

Patients describe primary focal axillary hyperhidrosis in remarkably similar terms. Sweat that begins independently of heat or activity. Visible patches that appear within minutes of putting on a shirt. A lifetime of choosing dark colours, of carrying a change of top, of avoiding pale fabrics and of declining the social situations where the condition would be visible. Many people have lived with this for years before considering treatment, often because they were not aware it was a recognised medical condition with established treatment options.

Hyperhidrosis is not a cosmetic concern in the conventional sense. The treatment we provide for axillary sweating sits at the medical end of injectable practice. The assessment and the conversation reflect that.

What is actually happening physiologically

Sweat is produced by two main types of glands. Eccrine glands, distributed across the body but concentrated in the underarms, palms, soles and forehead, produce the watery sweat associated with thermoregulation. Apocrine glands, concentrated in the axillae, produce a thicker secretion that interacts with skin bacteria to produce body odour. Both contribute to underarm wetness, but eccrine glands produce most of the volume.

Eccrine glands are unusual within the sympathetic nervous system. Although most sympathetic postganglionic nerves use noradrenaline as their neurotransmitter, eccrine sudomotor nerves use acetylcholine. This is a useful quirk of the anatomy because it means that interrupting acetylcholine release at the neuromuscular junction equivalent in the gland substantially reduces sweat production. That is the mechanism by which neuromodulator treatment works in this region.

How the treatment works mechanistically

Botulinum toxin type A binds to nerve terminals at the neuromuscular junction (or, in the case of sweat glands, the equivalent neuro glandular junction) and prevents the release of acetylcholine. Without acetylcholine reaching the gland, the eccrine sweat producing apparatus is functionally silenced. The blockade is reversible. Over months, new nerve terminals sprout and sweat production gradually returns to baseline.

Published clinical trials have shown that, at four weeks post treatment, around 94 percent of treated patients show meaningful reduction in axillary sweating compared with placebo. Average sweat rates fall from baseline values that can exceed 190 milligrams per minute to under 30 milligrams per minute in well responding patients. The duration of effect for hyperhidrosis treatment tends to be longer than the equivalent dose used in muscular cosmetic indications, with median first treatment durations around five and a half months and repeated treatment durations around eight and a half months.

When this treatment is indicated

The clinical picture that responds best to neuromodulator treatment is primary focal axillary hyperhidrosis: bilateral, symmetrical, idiopathic excessive sweating of the underarms, beginning typically in adolescence or young adulthood, occurring at least weekly, with no obvious medical cause. There is a validated scoring instrument (the Hyperhidrosis Disease Severity Scale) that helps quantify the impact, and we use it as part of consultation.

Patients who fit the picture have usually tried, and exhausted, the available topical strategies. Aluminium chloride antiperspirants in over the counter and prescription strengths are the conventional first line and remain useful for some, but they irritate the skin in many users and provide insufficient control in moderate to severe presentations. Once topical strategies have been adequately trialled, neuromodulator treatment becomes a clinically appropriate option.

When this treatment is not the right answer

Several presentations look like primary focal axillary hyperhidrosis but warrant different evaluation. Generalised sweating affecting multiple body regions or beginning in adulthood often reflects an underlying medical condition (thyroid dysfunction, diabetes, infection, medication side effect, hormonal change) and should be investigated by a general practitioner before cosmetic neuromodulator treatment is considered. Sweating associated with significant systemic symptoms requires medical workup. Sweating in only one underarm, or beginning suddenly without history, also calls for evaluation outside our scope.

This is part of why a thorough history matters at consultation. Treating focal axillary symptoms when the underlying cause is generalised or systemic does not address the actual problem and can delay appropriate care.

What an underarm hyperhidrosis treatment session involves

The treatment itself is performed in clinic and takes around twenty to thirty minutes. After confirming the assessment and obtaining consent, the underarm is mapped using a starch iodine test or by clinical observation to identify the area of active sweating. Multiple small injections are placed across the affected area, typically separated by about one and a half centimetres. The total dose is divided between the two sides and is generally generally tolerated with minimal pain.

Topical anaesthetic is applied if the patient prefers, although many patients find the procedure comfortable without it. Bruising can occur at injection points and resolves within a few days. There is no downtime in any practical sense. Patients return to normal activity immediately, with the conventional advice to avoid heavy exercise for the same evening.

What to expect in the first week, month and beyond

Onset of effect is gradual rather than immediate. Most patients begin noticing reduced sweating within three to seven days, with full effect at around two weeks. Some patients feel it sooner. The sensation is often described as a relief rather than an absence: the underarm feels normal in a way it has not for years, and the constant low grade vigilance about sweat patches falls away.

The duration varies. First treatments often last between four and seven months, with subsequent treatments commonly lasting longer as the cumulative neuromuscular dampening extends slightly. The plan is built around clinical assessment at follow up rather than a rigid retreatment calendar. If response begins to wane, retreatment is scheduled. If the response continues, the next treatment is deferred.

Compensatory sweating: a question worth asking

Patients sometimes worry that if axillary sweating is reduced, the body will compensate by sweating more elsewhere. The clinical evidence on this is reassuring. Compensatory sweating after focal axillary neuromodulator treatment is rare and, when it occurs, is typically mild and not in the same league as the compensatory sweating sometimes reported after surgical sympathectomy.

This matters because surgical sympathectomy was historically considered for severe hyperhidrosis and is associated with a substantial risk of permanent compensatory sweating elsewhere. Neuromodulator treatment offers a meaningful proportion of the same benefit without that consequence and is reversible, which is why it has become the preferred approach for most focal axillary cases.

Side effects and what we monitor

Local side effects (small bruise at an injection point, brief tenderness, occasional small subcutaneous lump that resolves over days) are the most common reported issues. Headache is sometimes reported in the first day or two and is generally mild. Reduction of underarm odour often follows reduction in sweat production because the apocrine secretion has less to mix with on the skin surface.

Rare but reportable side effects include weakness in the muscles immediately around the injection area (which can briefly affect grip strength if treatment encroaches on the borders of the axilla), allergic reactions, and very rarely systemic symptoms. These are discussed at consent. Patients are given written aftercare and a direct contact for the practitioner if any concerns arise after the appointment.

Why we do not name the prescription product

Australian regulation prohibits the advertising of Schedule 4 prescription medicines to the public. The TGA has been increasingly active in enforcing this provision in the cosmetic injectables sector, including for hyperhidrosis treatment where the same regulatory class of product is used. We can, and do, talk in clinical detail about the mechanism of action, the dose ranges, the response profile, the side effect profile and the safety considerations. We do not name brands, abbreviate brand names, or otherwise identify products to the public, because the law explicitly prohibits us from doing so.

AHPRA September 2025 and what this means for hyperhidrosis treatment

The AHPRA guidelines for nonsurgical cosmetic procedures that came into force in September 2025 require an in person or video consultation with the prescribing practitioner each time a cosmetic injectable is prescribed. For hyperhidrosis treatment, where retreatment is typically scheduled around the timing of returning sweat, this means each retreatment cycle includes a consultation with the practitioner. Asynchronous prescribing by text or online is no longer acceptable.

The same guidelines tightened suitability assessment requirements. For hyperhidrosis specifically, this includes screening for systemic causes that might better explain the patient’s symptoms, confirming that adequate topical treatment has been trialled, and discussing realistic expectations of duration and the need for retreatment.

Cost framing and what we do not do

We do not run promotional pricing, time limited offers, multi session bundles or any of the inducement style structures that AHPRA explicitly cautions against. Each treatment is priced on the basis of the actual product and time involved, and quoted in writing as part of the consultation. Patients are given the full picture in advance, including the realistic timing of likely retreatment.

Hyperhidrosis treatment can be claimable through Medicare in certain clinical circumstances if specific criteria are met and a referral pathway is followed, but the threshold and the documentation requirements vary and have been progressively tightened. We discuss the current eligibility framework at consultation rather than promising a particular outcome.

Working with Corey

Corey Anderson is the only practitioner at Core Aesthetics. Registered with the Nursing and Midwifery Board of Australia since January 1996 (AHPRA NMW0001047575), Corey runs a one practitioner, low volume model in Oakleigh. For hyperhidrosis treatment, this matters in a specific way: the consistency of injection technique and treatment mapping across years of repeated visits supports the kind of incremental refinement that produces stable, predictable results.

Patients see Corey at every visit. Treatment notes carry the dose, the mapping pattern and the response duration forward across years. This continuity is a deliberate counterweight to clinics where the injector rotates and the response profile has to be relearned at each visit.

The Melbourne south east context

Core Aesthetics operates from 12A Atherton Road, Oakleigh. Patients travel for hyperhidrosis treatment from across the south east corridor (Hughesdale, Huntingdale, Chadstone, Clayton, Mount Waverley, Glen Waverley, Wheelers Hill), the bayside strip and the inner east. The clinic is a short walk from Oakleigh station, with off street parking available.

For a treatment that recurs roughly twice a year, accessibility matters. Patients who live within reasonable travel of clinic find the cycle straightforward. Those who travel longer distances may prefer to coordinate appointments with other commitments in the area.

A note on quality of life

Many of the patients we see for hyperhidrosis treatment describe the most meaningful change after treatment as something other than the sweat reduction itself. The reduction is the mechanism. The change is in everything that the sweat made small. The shirt that no longer needs to be checked. The handshake that no longer comes with a deflection. The presentation that no longer has to be planned around lighting and choice of fabric. The simple lightness of being able to dress for the day without the underarm being the variable that has to be managed first.

This is not a cosmetic claim. It is the reason hyperhidrosis is recognised in the medical literature as a condition with substantial impact on quality of life, and why the validated severity scales focus heavily on functional and social outcomes rather than millilitres of sweat. The treatment, when it is appropriate and well delivered, addresses the functional impact more than it addresses any visible appearance.

How retreatment cycles tend to settle

The first treatment is informational. It establishes how the patient responds, the duration of effect they get, and any modifications that should be made for the second cycle. The second treatment is usually adjusted in light of the first response, sometimes with small changes to mapping, dose distribution or timing. By the third or fourth treatment, the cycle has typically settled into a predictable rhythm that fits around the patient life.

Some patients prefer to time treatment ahead of summer or ahead of specific commitments. Others prefer to retreat as soon as they notice the first early return of sweating. Both patterns are clinically reasonable and can be supported. The plan is the patient plan, not a clinic schedule.

Why underarm hyperhidrosis is often diagnosed late

Patients commonly present in their late twenties or thirties having lived with the condition since adolescence. The reasons for delayed presentation are predictable. Many people assume that excessive underarm sweating is a personal characteristic rather than a medical condition. Others have raised it with general practitioners and been told to try stronger antiperspirants without further investigation. Some have read about treatment online but assumed it was unsuitable for any reason: cost, perceived risk, the assumption that it would not help.

The clinical picture is not subtle. Bilateral, symmetrical excessive sweating beginning in adolescence, occurring at least weekly, interfering with daily life, in the absence of obvious medical cause, fits the diagnosis. There is a validated scoring instrument (the Hyperhidrosis Disease Severity Scale) and a body of clinical guidance on management. Patients who fit the picture deserve a clear conversation about treatment options.

A note on the practitioner conversation

The consultation for hyperhidrosis treatment is different in tone from a cosmetic injectables consultation. We are talking about a condition with measurable impact, an established treatment with strong published evidence, and a patient who has often spent years managing symptoms before considering medical care. The conversation is medical first. The cosmetic injectables framing is incidental to the clinical reality.

Booking a consultation

Hyperhidrosis consultations are individually scheduled to allow adequate time for history, assessment, mapping and treatment in a single appointment where appropriate. The consultation is a clinical assessment, not a treatment commitment. If history suggests that the presentation requires evaluation outside our scope, we say so directly and refer back to general practice. If the indication is clear and the patient is ready to proceed, treatment can be performed in the same visit. Results vary between individuals and the plan is built around the specific clinical picture and goals of the person in front of us.

Why The Visible Effect Often Lags The Patient’s Subjective Sense Of Improvement

Patients receiving injectable treatment for axillary hyperhidrosis often report subjective improvement before the objective measurement would confirm a meaningful change. The reasons are partly neurological and partly psychological. The eccrine glands respond to acetylcholine released at the postganglionic sympathetic nerve terminals, and the injectable compound interrupts that signalling at the neuromuscular and neuroglandular junction over a gradient of days. Subjective sweat awareness is highly responsive to small changes in baseline; a patient who has been monitoring axillary moisture continuously for years notices early reduction quickly even when the absolute change is still modest.

By week two, most patients describe a meaningful change in the practical patterns of their day. By week three to four, the response has stabilised and the four week review documents the actual extent of the effect. Patients are encouraged to bring observations from real world settings to the review appointment, including specific scenarios that previously caused difficulty, because that contextual reporting is more clinically useful than abstract before and after comparisons. Where the response is incomplete, additional product can be considered at the review; where the response is complete, the next conversation is about expected duration and retreatment timing.

Duration in the axilla is variable. Australian and international clinical experience describes a typical range of four to seven months for axillary work, with some patients maintaining effect closer to nine months. The variation reflects individual differences in metabolism, baseline sweat gland density, and the cumulative effect of repeated treatment cycles. Patients who return for retreatment over multiple years often find their preferred retreatment interval lengthens after the first two or three cycles as the response pattern is documented for the individual.

The treatment does not address the underlying neurology of primary hyperhidrosis. It interrupts a downstream signalling step for a defined duration. Patients who want a less recurrent intervention sometimes ask about endoscopic thoracic sympathectomy; the surgical option is well described in the literature but carries a documented incidence of compensatory sweating elsewhere on the body and is considered a more invasive choice with different risk benefit considerations. The honest comparison is part of the consultation conversation, conducted by Corey Anderson, Registered Nurse, AHPRA NMW0001047575.